文献速递慢阻肺

合并症COPD患者急性加重行动计划:一项随机对照试验

Exacerbation action plans for patients with COPD and comorbidities: a randomised controlled trial.
PubMed 文献 · Eur Respir J · 2019-11-07

这项国际随机对照试验评估了合并症COPD患者接受个体化多病种急性加重行动计划训练后,COPD急性加重天数是否少于常规照护。结果显示,干预未显著减少每年每患者COPD急性加重天数,但缩短了单次急性加重持续时间,并降低了至少一次呼吸相关住院的概率,且未增加全因死亡率。

要点

  • 个体化行动计划未显著减少COPD急性加重天数。
  • 干预缩短了单次COPD急性加重持续时间。
  • 干预降低了至少一次呼吸相关住院的风险。

核心结论

  • 个体化急性加重行动计划未显著减少合并症COPD患者的急性加重天数,但缩短了单次急性加重持续时间并降低了至少一次呼吸相关住院风险,且未增加全因死亡率。

研究设计与样本

  • 国际随机对照试验,纳入GOLD II-IV级且至少有一种合并症(缺血性心脏病、心力衰竭、糖尿病、焦虑、抑郁)的COPD患者,干预组n=102,常规照护组n=99。
  • 每日症状日记持续12个月,主要结局采用意向性治疗分析评估每年每患者COPD急性加重天数。

主要发现

  • 每年每患者COPD急性加重天数:干预组中位数9.6天(IQR 0.7-31.1),常规照护组中位数15.6天(IQR 3.0-40.3),IRR 0.87(95%CI 0.54; 1.39),p=0.546。
  • 单次COPD急性加重持续时间:干预组中位数8.1天(IQR 4.8-10.1),常规照护组中位数9.5天(IQR 7.0-15.1),p=0.021。
  • 呼吸相关住院总数无组间差异(IRR 0.76,95%CI 0.42; 1.35,p=0.348),但干预组至少一次呼吸相关住院的概率低于常规照护组(相对风险0.55,95%CI 0.35; 0.87,p=0.008)。
  • 全因住院无组间差异(IRR 1.07,95%CI 0.66; 1.72),死亡率无组间差异(干预组n=4(3.9%),常规照护组n=7(7.1%),相对风险0.55,95%CI 0.17; 1.84)。

临床怎么用

  • 对合并症COPD患者可考虑使用个体化急性加重行动计划,以缩短单次急性加重持续时间并降低至少一次呼吸相关住院风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This international randomised controlled trial evaluated whether COPD patients with comorbidities, trained in using patient-tailored multidisease exacerbation action plans, had fewer COPD exacerbation days than usual care (UC).COPD patients (Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification II-IV) with ≥1 comorbidity (ischaemic heart disease, heart failure, diabetes, anxiety, depression) were randomised to a patient-tailored self-management intervention (n=102) or UC (n=99). Daily symptom diaries were completed for 12 months. The primary outcome "COPD exacerbation days per patient per year" was assessed using intention-to-treat analyses.No significant difference was observed in the number of COPD exacerbation days per patient per year (self-management: median 9.6 (interquartile range (IQR) 0.7-31.1); UC: median 15.6 (IQR 3.0-40.3); incidence rate ratio (IRR) 0.87 (95% CI 0.54; 1.39); p=0.546). There was a significantly shorter duration per COPD exacerbation for self-management (self-management: median 8.1 (IQR 4.8-10.1) days; UC: median 9.5 (IQR 7.0-15.1) days; p=0.021), with no between-group differences in the total number of respiratory hospitalisations (IRR 0.76 (95% CI 0.42; 1.35); p=0.348), but a lower probability of ≥1 for respiratory-related hospitalisation compared to UC (relative risk 0.55 (95% CI 0.35; 0.87); p=0.008). No between-group differences were observed in all-cause hospitalisations (IRR 1.07 (95% CI 0.66; 1.72)) or mortality (self-management: n=4 (3.9%); UC: n=7 (7.1%); relative risk 0.55 (95% CI 0.17; 1.84)).Patient-tailored exacerbation action plans for COPD patients with comorbidities did not significantly reduce exacerbation days, but reduced the duration per COPD exacerbation and the risk of having at least one respiratory-related hospitalisation during follow-up, without excess all-cause mortality.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Lenferink A, van der Palen J, van der Valk PDLPM, et al. Exacerbation action plans for patients with COPD and comorbidities: a randomised controlled trial. Eur Respir J. 2019. PMID: 31413163. doi:10.1183/13993003.02134-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。